Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 45% Improvement Relative Risk Hospitalization time 7% c19early.org/mf Chertok Shacham et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 359 patients in Israel (April 2020 - March 2021) Study compares with insulin, results vs. placebo may differ Lower mortality with metformin (p=0.00014) Chertok Shacham et al., Medicine, doi:10.1097/md.0000000000032650 Favors metformin Favors insulin
Blood glucose control with different treatment regimens in type 2 diabetes patients hospitalized with COVID-19 infection: A retrospective study
Chertok Shacham et al., Medicine, doi:10.1097/md.0000000000032650
Chertok Shacham et al., Blood glucose control with different treatment regimens in type 2 diabetes patients hospitalized with COVID-19.., Medicine, doi:10.1097/md.0000000000032650
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 359 COVID-19 patients with diabetes in Israel, showing lower mortality in the other treatments group compared to the insulin group, with 80% of the other treatments group receiving metformin. Groups refer to use during hospitalization, however most are likely continuation of existing diabetes treatment.
risk of death, 44.9% lower, RR 0.55, p < 0.001, treatment 39 of 162 (24.1%), control 86 of 197 (43.7%), NNT 5.1, 80% of treatment patients received metformin.
hospitalization time, 6.7% lower, relative time 0.93, p = 0.50, treatment 162, control 197, 80% of treatment patients received metformin.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chertok Shacham et al., 20 Jan 2023, retrospective, Israel, peer-reviewed, 3 authors, study period 1 April, 2020 - 31 March, 2021, this trial compares with another treatment - results may be better when compared to placebo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Medicine ® Observational Study Blood glucose control with different treatment regimens in type 2 diabetes patients hospitalized with COVID-19 infection A retrospective study Elena Chertok Shacham, MDa,* , Nimra Maman, BSb, Avraham Ishay, MDa,c Abstract Coronavirus disease (COVID-19) is closely associated with hyperglycemia and a worse prognosis in patients with a previous diagnosis of type 2 diabetes mellitus. A few studies investigated the effects of diabetes treatment regimens in these patients during hospitalization. Here, we evaluate the impact of insulin and non-insulin therapy on glucose control in patients with type 2 diabetes admitted with COVID-19. This is a retrospective study including 359 COVID-19 patients with type 2 diabetes. Patients were divided into 2 groups according to diabetes treatment during hospitalization. The first group included patients treated with insulin only, and the second group patients treated with other antidiabetic agents with or without insulin. Average blood glucose was higher in the insulin-only treatment group (201 ± 66 mg/dL vs 180 ± 71 mg/dL, P = .004), even after excluding mechanically ventilated patients (192 ± 69 vs 169 ± 59 mg/dL, P = .003). In patients with moderate severity of COVID-19, average blood glucose was also significantly higher in the insulin-only treated group (197 ± 76 vs 168 ± 51 mg/dL, P = .001). Most patients (80%) in the combination treatment group received metformin. Moderately affected COVID-19 patients with type 2 diabetes could safely be treated with antihyperglycemic medications with or without insulin. Abbreviations: GLP-1 RA = glucagon-like peptide-1 receptor agonists, HbA1c = hemoglobin A1c, SGLT-2 = sodium-glucose transport protein. Keywords: COVID-19, diabetes therapy in the hospital, type 2 diabetes hospitalized, the mortality rate was 28.8% in patients with diabetes and/or uncontrolled hyperglycemia compared with 6.2% in patients with normoglycemia.[9] In another retrospective study of >7000 COVID-19 patients, the authors noticed that in COVID-19 patients with preexisting diabetes, well-controlled blood glucose was correlated with reduced risk of allcause mortality and less frequent complications, including adult respiratory distress syndrome, acute kidney injury, and septic shock.[10] Hyperglycemia can trigger endothelial damage, and over-inflammation via an increase in the expression of cytokines, including interleukin-6 and tumor necrosis factor-α in severely ill COVID-19 patients.[11] Recent studies showed that patients with uncontrolled type 2 diabetes had reduced titers of COVID-19 neutralizing antibodies after severe acute respiratory syndrome coronavirus 2 vaccination and higher rates of breakthrough COVID-19 infection one year after vaccination.[12,13] Insulin is well-established as the most appropriate pharmacologic agent for effectively controlling glycemia in hospitals, particularly in critically ill patients.[14] Insulin regimens that
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit